annual meeting program - American Society of Clinical Oncology

Saturday, June 5, 2010
Brd. 7 The efficacy of interferon-� and temozolomide combination therapy for
newly diagnosed primary glioblatoma: Multicenter study. (Abstract #2015)
K. Motomura, A. Natsume, M. Fujii, M. Ito, H. Namba, T. Abe, Y. Nakasu,
R. Watanabe, K. Wakai, T. Wakabayashi
Brd. 8 Effect of combined therapy with temsirolimus (CCI-779), temozolomide
(TMZ), and radiation (RT) in newly diagnosed glioblastoma multiforme (GBM)
patients on immune suppression: Results from NCCTG N027D. (Abstract
#2016)
J. N. Sarkaria, E. Galanis, M. P. Gustafson, A. B. Dietz, W. Wu, P. D. Brown,
J. H. Uhm, C. Giannini, K. A. Jaeckle, J. C. Buckner
Brd. 9 Testosterone levels in men undergoing treatment for malignant gliomas.
(Abstract #2017)
M. Holdhoff, X. Ye, L. Blair, S. A. Grossman, J. O. Blakeley
Brd. 10 NCCTG phase II trial of bevacizumab in combination with sorafenib in
recurrent GBM. (Abstract #2018)
E. Galanis, K. A. Jaeckle, S. Anderson, T. J. Kaufmann, J. H. Uhm, C. Giannini,
S. Kumar, D. W. Northfelt, P. J. Flynn, J. C. Buckner
Brd. 11 Heterogeneity of response to bevacizumab in multifocal and multicentric
glioblastomas. (Abstract #2019)
S. S. Ong, V. K. Puduvalli
Brd. 12 Change in pattern of relapse in newly diagnosed high-grade glioma following
bevacizumab therapy. (Abstract #2020)
M. L. Gruber, S. Kunnakkat, P. Medabalmi, D. B. Gruber, J. Golfinos, E. Parker,
A. Narayana
Brd. 13 Radiographic patterns of relapse in glioblastoma. (Abstract #2021)
M. C. Chamberlain
Brd. 14 Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on
glioblastoma patients given antiangiogenetic drugs? (Abstract #2022)
E. Franceschi, A. A. Brandes, A. Tosoni, A. Bacci, L. Morandi, F. Spagnolli,
R. Degli Esposti, S. Bartolini, R. Poggi, M. Ermani
Brd. 15 Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation
therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed
glioblastoma multiforme (GBM). (Abstract #2023)
J. J. Vredenburgh, A. Desjardins, D. A. Reardon, K. Peters, J. Kirkpatrick,
J. E. Herndon, J. Marcello, L. Bailey, S. Threatt, H. S. Friedman
Brd. 16 Diffusion restriction as a predictor of response in recurrent glioblastoma
patients receiving bevacizumab. (Abstract #2024)
J. Wu, M. R. Gilbert, J. F. De Groot, W. A. Yung, V. K. Puduvalli
Brd. 17 Deletion of NFKBIA in malignant gliomas. (Abstract #2025)
M. Bredel, A. Yadav, J. Renfrow, D. Scholtens, C. Bredel, J. Chandler, A. Scheck,
K. D. Aldape, A. Chakravarti, G. Harsh
Brd. 18 Use of perfusion MR imaging for differentiation between tumor progression
and pseudo-progression in recurrent glioblastoma multiforme. (Abstract
#2026)
C. Heidemans-Hazelaar, A. Y. Verbeek, H. M. Oosterkamp Sr., B. Van der Kallen,
C. J. Vecht
Brd. 19 Prognostic impact of stem cell marker CD133 in 61 glioblastoma patients
treated with concomitant chemoradiation: A prospective study. (Abstract
#2027)
P. Metellus, I. Nanni-Metellus, C. Delfino, C. Colin, B. Coulibaly, F. Fina,
O. L. Chinot, D. Figarella-Branger, L. Ouafik
Brd. 20 CD133 expression in glioblastoma recurring after radiation therapy.
(Abstract #2028)
T. Cenci, R. Pallini, M. Martini, L. R. Vitiani, N. Montano, F. Pierconti, R. De Maria,
L. Larocca
119
SATURDAY